Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q2L4Q9

UPID:
PRS53_HUMAN

ALTERNATIVE NAMES:
Polyserine protease 3

ALTERNATIVE UPACC:
Q2L4Q9

BACKGROUND:
The enzyme Serine protease 53, alternatively known as Polyserine protease 3, exhibits a specialized function by degrading fibrinogen alpha chains and pro-urokinase-type plasminogen activator. With its unique enzymatic activity, it stands as a significant player in the regulation of fibrinolysis and plasminogen activation, essential for blood clot resolution and tissue repair.

THERAPEUTIC SIGNIFICANCE:
The exploration of Serine protease 53's function offers a promising avenue for therapeutic intervention. Given its critical role in the fibrinolytic pathway, targeting this protease could lead to innovative treatments for managing and preventing thrombosis, enhancing patient outcomes in cardiovascular diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.